Madrigal Pharmaceuticals Files 8-K for Security Holder Vote

Ticker: MDGL · Form: 8-K · Filed: Jun 20, 2025 · CIK: 1157601

Sentiment: neutral

Topics: corporate-governance, shareholder-vote

Related Tickers: MDGL

TL;DR

MDGL filed an 8-K for a shareholder vote - details TBD.

AI Summary

Madrigal Pharmaceuticals, Inc. filed an 8-K on June 20, 2025, to report the submission of matters to a vote of its security holders. The filing does not disclose specific details about the matters to be voted on, but it indicates that a vote will be held.

Why It Matters

This filing signals that Madrigal Pharmaceuticals is preparing for a shareholder vote, which could involve significant corporate decisions or changes that may impact investors.

Risk Assessment

Risk Level: medium — The filing itself is procedural, but the underlying matters to be voted on could carry significant risk or opportunity for the company and its shareholders.

Key Players & Entities

FAQ

What specific matters will be submitted for a vote by Madrigal Pharmaceuticals' security holders?

The 8-K filing states that matters are being submitted to a vote of security holders, but it does not specify what those matters are. Further information would likely be found in a proxy statement or subsequent filings.

When is the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported is June 20, 2025.

What is the Commission File Number for Madrigal Pharmaceuticals?

The Commission File Number for Madrigal Pharmaceuticals is 001-33277.

In which state is Madrigal Pharmaceuticals incorporated?

Madrigal Pharmaceuticals is incorporated in Delaware.

What is the principal executive office address for Madrigal Pharmaceuticals?

The principal executive office address is Four Tower Bridge 200 Barr Harbor Drive, Suite 200 West Conshohocken, Pennsylvania 19428.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 20, 2025 regarding MADRIGAL PHARMACEUTICALS, INC. (MDGL).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing